JFS Wealth Advisors’s UroGen Pharma URGN Stock Holding History

JFS Wealth Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$10K	–	1973
2021 Q4	$10K	Buy	+1,000	New	+$14.1K	﹤0.01%	691

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

JFS Wealth Advisors's URGN Position: Q1 2022 in Review

JFS Wealth Advisors sold out of UroGen Pharma (URGN) in Q1 2022, closing a stake of 1,000 shares — an estimated $10K sold.

JFS Wealth Advisors first reported a position in URGN in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 83 funds tracked by Wall St. Rank hold URGN as of Q1 2022.

JFS Wealth Advisors reported no remaining UroGen Pharma position as of Q1 2022 after selling out during the quarter.
JFS Wealth Advisors sold 1,000 UroGen Pharma shares in Q1 2022, an estimated $10K.
JFS Wealth Advisors first reported a position in UroGen Pharma in Q4 2021 and held it in 1 quarter.
JFS Wealth Advisors's UroGen Pharma position peaked at $10K in Q4 2021.
83 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2022.

Based on JFS Wealth Advisors's 13F filing for Q1 2022, filed 2 May 2022.